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In a multicentre European hospital study we measured 
influenza vaccine effectiveness (IVE) against A(H3N2) 
in 2016/17. Adjusted IVE was 17% (95% confidence 
interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) 
among 65–79-year-olds and 13% (95% CI: −15 to 30) 
among those ≥ 80 years. As the A(H3N2) vaccine com-
ponent has not changed for 2017/18, physicians and 
public health experts should be aware that IVE could 
be low where A(H3N2) viruses predominate.
In 2016/17, the influenza season in Europe was char-
acterised by an early start (week 46, 2016) and a pre-
dominance of A(H3N2) viruses. Overall, 89% of strains 
reported to the European Centre for Disease Prevention 
and Control (ECDC) were A(H3N2) viruses [1]. High hos-
pitalisation rates and case fatality ratios were reported 
among persons aged 65 years and above [2]. The 
I-MOVE + (Integrated Monitoring of Vaccines in Europe 
plus) hospital network early estimates, suggested a low 
2016/17 seasonal influenza vaccine effectiveness (IVE) 
against hospitalisation with influenza A(H3N2) among 
persons aged 65 years and above in the European 
Union (EU) [3].
Since the A(H3N2) vaccine component has not changed 
in 2017/18, we present the final 2016/17 season IVE 
against hospitalisation with influenza A(H3N2) among 
persons aged 65 years and above in Europe, to inform 
on the level of IVE that can be expected against 
A(H3N2) in the upcoming 2017/18 season.
Study design 
We conducted a multicentre hospital-based test-neg-
ative design (TND) case-control study in 27 hospitals 
from 10 countries (Croatia, Finland, France, Hungary, 
Italy, Lithuania, the Netherlands, Portugal, Romania 
and Spain) according to a generic protocol adapted 
to each local setting [4]. The detailed methods are 
described elsewhere [5]. In brief, hospital teams identi-
fied and swabbed patients aged 65 years and above, 
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Table 1
Characteristics of influenza A(H3N2) hospitalised cases (n = 1,073) and test-negative controls (n = 1,541), I-MOVE + study, 
Europe, influenza season 2016/17
Influenza A(H3N2) cases 
 
(n = 1,073)
Controls (n = 1,541)
Median age in years (range) 81 (65–102) 80 (65–102)
Characteristic n/Na % n/Na %
Aged 65–69 years 457/1,073 42.6 770/1,541 50.0
Sex = male 516/1,072 48.1 815/1,535 53.1
2016/17 seasonal influenza vaccination 556/1,073 51.8 894/1,541 58.0
2015/16 seasonal influenza vaccination 578/1,054 54.8 896/1,525 58.8
Current and previous vaccination status
2016/17 seasonal vaccine only 46/1,054 4.4 99/1,525 6.5
2015/16 seasonal vaccine only 73/1,054 6.9 112/1,525 7.3
2015/16 and 2016/17 seasonal vaccines 505/1,054 47.9 784/1,525 51.4
Type of 2016/17 vaccine
Not vaccinated 517/1,007 48.2 647/1,421 42.0
Inactivated subunit egg 243/1,007 22.6 431/1,421 28.0
Inactivated split virion egg 229/1,007 21.3 321/1,421 20.8
Adjuvanted 18/1,007 1.7 22/1,421 1.4
Underlying conditions
Diabetes mellitus 325/1,072 30.3 473/1,540 30.7
Heart disease 710/1,070 66.4 1,032/1,541 67.0
Lung disease 392/1,069 36.7 672/1,534 43.8
Cancer 201/1,069 18.8 369/1,533 24.1
Renal disease 223/1,071 20.8 319/1,539 20.7
Stroke 125/879 14.2 176/1,287 13.7
Rheumatologic disease 157/1,070 14.7 341/1,539 22.2
Obesityb 124/1,062 11.7 154/1,527 10.1
Any underlying condition 996/1,063 93.7 1,456/1,531 95.1
At least two underlying conditions 776/1,025 75.7 1,206/1,491 80.9
Functional impairment 399/1,066 37.4 588/1,529 38.5
Hospitalisations in past 12 months 353/1,063 33.2 668/1,526 43.8
Current smoker 182/901 20.2 318/1,220 26.1
Potential for misclassification
Antivirals received before swabbing 177/1,069 16.0 90/1,535 5.8
Swabbing within 3 days of symptom onset 653/1,073 58.7 876/1,541 56.2
Study sites
Croatia 31/1,073 2.9 13/1,541 0.8
Finland 20/1,073 1.9 50/1,541 3.2
France 119/1,073 11.1 209/1,541 13.6
Hungary 8/1,073 0.7 19/1,541 1.2
Italy 73/1,073 6.8 136/1,541 8.8
Lithuania 67/1,073 6.2 58/1,541 3.8
Navarre, Spain 242/1,073 22.6 290/1,541 18.8
The Netherlands 40/1,073 3.7 63/1,541 4.1
Portugal 49/1,073 4.6 29/1,541 1.9
Romania 90/1,073 8.4 103/1,541 6.7
Spainc 334/1,073 31.1 571/1,541 37.1
I MOVE+: Integrated Monitoring of Vaccines in Europe plus.
a N represents the total number of cases or controls with available information.
b Defined as body mass index ≥ 30 kg/m2.
c Excluding Navarre.
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hospitalised with signs compatible with a severe acute 
respiratory infection (SARI) defined as at least one 
systemic and one respiratory sign or symptom. Swabs 
were tested with reverse-transcriptase polymerase 
chain reaction (RT-PCR) for influenza A(H3N2), A(H1N1)
pdm09 and B. We compared the odds of vaccination 
between patients positive for influenza A(H3N2) virus 
and those negative for any influenza virus. We calcu-
lated IVE as (1-odds ratio (OR)).
We measured IVE stratified by age group (65–79 year-
olds and ≥ 80 year-olds), presence of underlying condi-
tions (diabetes mellitus, cancer, heart or lung disease, 
and presence of at least two underlying chronic dis-
eases) and 2015/16 seasonal influenza vaccination sta-
tus. In a one-stage approach, using logistic regression 
with the study site as a fixed effect, we adjusted IVE 
estimates for date of symptoms onset, age (as cubic 
splines) and individual underlying conditions. Using 
patients unvaccinated in both 2015/16 and 2016/17 
seasons as a reference, we computed the effectiveness 
of being vaccinated in 2015/16 season only, in 2016/17 
season only and in both seasons.
Vaccine effectiveness against influenza 
A(H3N2) in 2016/17
We included 1,073 influenza A(H3N2) cases, nine 
A(H1N1)pdm09 cases, 13 cases of influenza B and 1,541 
controls between week 47, 2016 and week 14, 2017. 
Due to the small number of cases, we were not able 
to measure IVE against influenza A(H1N1)pdm09 and B. 
We excluded these 22 records from all analyses.
The median age of A(H3N2) cases was 81 years (range: 
65−102 years) while that of controls was 80 (range: 
65−102 years). Ninety-four percent of cases and 95% 
of controls had at least one underlying condition 
(p = 0.14). Controls were more likely than cases to have 
underlying lung disease (44 vs 37%, p < 0.05), rheuma-
tologic disease (22 vs 15%, p < 0.05) and cancer (24 vs 
19%, p < 0.05), to have been hospitalised in the past 12 
months (44 vs 33%, p < 0.05) and to be current smokers 
(26 vs 20%, p < 0.05) (Table 1).
The one-stage pooled adjusted IVE was 17% (95% con-
fidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 
to 43) among patients aged 65–79 years and 10% (95 
%CI: −15 to 30) among those aged 80 years and above. 
Among patients with specific underlying conditions, 
IVE ranged between 19% (95% CI: −1 to 35) among 
patients with heart disease and 35% (95% CI: 14 to 51) 
among patients with lung disease (Table 2).
The 2016/17 seasonal IVE was −2% (95% CI: −44 to 28) 
among patients who had received 2015/16 seasonal 
influenza vaccine and 39% (95 %CI: −3 to 59) among 
patients not vaccinated in 2015/16 (Table 2). Taking 
as a reference patients unvaccinated in 2015/16 and 
Table 2
Seasonal influenza vaccine effectiveness against influenza influenza A(H3N2) overall and stratified by patient 
characteristics, I-MOVE + study, Europe, influenza season 2016/17
Population and patient characteristics Vaccinated /cases % Vaccinated /controls % Adjusted IVE 95% CI
Aged 65 years and above - age/timea 556/1,073 52 894/1,541 58 17 1 to 31
Aged 65 years and above - full modela 544/1,041 52 868/1,494 58 14 −3 to 29
Aged 65–79 years - age/timea 175/457 38 382/770 50 25 2 to 43
Aged 80 years and above - age/timea 381/616 62 512/771 66 13 −12 to 32
According to underlying diseases
Diabetes mellitus 183/320 57 295/468 63 22 −8 to 44
Heart disease 378/703 54 622/1,024 61 19 −1 to 35
Lung disease 209/386 54 440/668 66 35 14 to 51
Cancer 105/198 53 227/362 63 21 −19 to 47
At least two underlying chronic diseases 414/767 54 732/1,196 61 17 −2 to 33
According to previous vaccination
Not vaccinated in 2015/16 46/473 10 99/623 16 39 −3 to 59
Vaccinated in 2015/16 502/572 88 776/887 87 −2 −44 to 28
Sensitivity analyses
Swabbed within 3 days 502/872 58 333/629 53 8 −16 to 28
No antivirals before swabbing 867/1,446 60 509/904 56 14 −3 to 29
I MOVE+: Integrated Monitoring of Vaccines in Europe plus.
a Variables used for adjustment:
-age/time: adjusted for study site, age and onset date (modelled as a restricted cubic spline with 3 and 4 knots respectively);
-full model: adjusted for study site, onset date, age (modelled as a restricted cubic spline with 3 and 4 knots respectively), lung diseases, 
heart diseases, diabetes, obesity, renal diseases, cancer and hospitalisation in the past 12 months;
-other estimates were adjusted for study site, onset date, age (modelled as a restricted cubic spline with 3 and 4 knots respectively) and 
hospitalisation in the past 12 months.
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2016/17, IVE for those vaccinated in 2015/16 only was 
19% (95% CI: −15 to 42) and IVE when vaccinated both 
in 2015/16 and 2016/17 was 15% (95 %CI: −3 to 30) 
(Table 3). 
Discussion
In the 2016/17 influenza season, A(H3N2) viruses 
largely predominated. IVE against hospitalisation with 
influenza A(H3N2) virus infection among persons aged 
65 years and above was low at 17%. The IVE point 
estimate was even lower (10%) among patients aged 
80 years and above. IVE was similar among patients 
with heart disease, diabetes mellitus and cancer. The 
IVE point estimate was higher among patients with 
lung disease. While 95% CIs were largely overlapping, 
the 2016/17 IVE point estimate was lower (IVE: −2%) 
among patients vaccinated also in 2015/16 than among 
those unvaccinated in 2015/16 (IVE: 39%).
Low IVE against influenza A(H3N2) among persons 
aged 65 years and above has been previously observed 
in hospital settings [6-8]. A recent meta-analysis meas-
ured that the pooled IVE against hospitalisation with 
influenza A(H3N2) in seasons when circulating and 
vaccine strains were antigenically different was 14% 
(95%  CI: −3 to 30) among persons aged 65 years and 
above [9]. It was 43% (95% CI: 33 to 53) in seasons 
when circulating and vaccine A(H3N2) strains were 
antigenically similar; 48% (95%  CI: 37 to 59) against 
influenza A(H1N1)pdm09 and 38% (95% CI: 25 to 53) 
against influenza B [9].
Based on specimens received from week 40/2016 to 
week 5/2017, available antigenic data from the World 
Health Organization (WHO) European Region indicated 
that most circulating viruses that could be analysed 
were considered as antigenically similar to the 2016/17 
vaccine component [10]. Consequently, European data 
supported the WHO recommendation to maintain the 
same vaccine component A/Hong Kong/4801/2014 
(clade 3C.2a) for influenza A(H3N2) in the 2017/18 sea-
son vaccine for the northern hemisphere [11]. However, 
one third of viruses isolated during the above-men-
tioned period could not be assigned to an antigenic 
reporting category, reflecting technical challenges or 
antigenic changes in circulating viruses. Genetic data 
from Europe centralised at the ECDC suggested that cir-
culating A(H3N2) viruses had undergone considerable 
genetic diversification during the above-mentioned 
period, with the emergence of subclusters within clade 
3C.2a and subclade 3C.2a1 [10].
In September 2017, WHO updated the A(H3N2) compo-
nent to A/Singapore/INFIMH-16-0019/2016 (subclade 
3C.2a1) in the 2018 seasonal vaccine for the southern 
hemisphere [12]. The latest WHO update on 2 October 
2017, reported that influenza A(H3N2) viruses were still 
predominating worldwide in September 2017. Further 
genetic information was not provided at this stage [13].
Our results taking patients unvaccinated in both 
2015/16 and 2016/17 seasons as a reference sug-
gested that influenza vaccination in 2015/16 and/or 
2016/17 reduced the risk of influenza-associated hos-
pitalisation among vaccinated patients. Our stratified 
results suggested that 2015/16 vaccination modified 
the 2016/17 IVE. Although too imprecise to be conclu-
sive, our results could suggest that patients vaccinated 
in both seasons benefited from a residual protection 
from the 2015/16 vaccine, with no additional effect of 
the 2016/17 vaccine uptake.
Conclusion 
Our results suggest a low IVE against hospitalised 
influenza A(H3N2) among persons aged 65 years and 
above, particularly among patients aged 80 years and 
above. They also suggest a modifying effect of 2015/16 
influenza vaccination on 2016/17 IVE. The A(H3N2) 
virus component included in the 2017/18 vaccine will 
remain the same as in the 2016/17 season. The lat-
est WHO influenza surveillance report suggests that 
influenza A(H3N2) viruses were predominating world-
wide in August 2017. Low IVE may be expected during 
the 2017/18 season in case of predominant circulation 
of A(H3N2) viruses. However, IVE against influenza 
A(H1N1)pdm09 and B are usually reported to be higher. 
Close monitoring of virological surveillance data will be 
required to prompt early promotion of complementary 
measures such as the use of antivirals or non-pharma-
ceutical interventions.
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Table 3
Seasonal influenza vaccine effectiveness against influenza 
A(H3N2) by vaccine uptake in 2015/16, 2016/17 and in 
both seasons, I-MOVE + study, Europe, influenza season 
2016/17
Vaccine uptake in 2015/16 
and 2016/17 influenza 
seasons
Cases Controls IVE 95% CI
Not vaccinated 427 524 Reference
2016/17 only 46 99 38 9 to 58
2015/16 only 70 111 19 −15 to 42
Vaccinated in both seasons 502 776 15 −3 to 30
CI: confidence interval; I-MOVE+: Integrated Monitoring of 
Vaccines in Europe plus; IVE: influenza vaccine effectiveness.
a Adjusted for study site, age and onset date (modelled as a 
restricted cubic spline with 3 and 4 knots, respectively).
The A(H3N2) vaccine components were A/Switzerland/2013 (3C.3a) 
in the 2015/16 seasonal vaccine and A/Hong Kong/2014 (3c.2a) 
in the 2016/17 seasonal vaccine.
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